At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 146 enrolled
Drug / intervention
AR101 powder provided in capsules & sachets +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)
In Brief
A Phase 3 clinical trial evaluating AR101 powder provided in capsules & sachets and Placebo powder provided in capsules & sachets for Peanut Allergy. Completed, enrolled 146 participants across 23 sites in 4 countries.
Detailed Summary
The purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to \< 4 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Allergy
CountriesFrance, Germany, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartDec 2018
Primary CompletionJul 2022
TodayJul 2026
First PostedNov 9, 2018
Enrollment StartDec 27, 2018
Primary CompletionJul 5, 2022
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 7.6 years ago
Interventions
AR101 powder provided in capsules & sachetsbiological
Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
Placebo powder provided in capsules & sachetsbiological
Study product formulated to contain only inactive ingredients for use as defined in the protocol